Phase I/II clinical trials of CTLA-4 blockade
Antibodies | Dose | Cancer | No. of cases | No. of objective responses | Reference |
---|---|---|---|---|---|
MDX-010 | 3 mg/kg, 1.5 mg/kg every 4 weeks | Lymphoma | 4 | 2 | (63) |
Colon | 3 | 0 | |||
Prostate | 4 | 0 | |||
MDX-010 | 3 mg/kg | Prostate | 14 | 2 (≥50% decrease of prostate-specific antigen) | (58) |
MDX-010 | 3 mg/kg every 3 weeks | Renal | 21 | 1 partial response | (66) |
3 mg/kg, 1 mg/kg every 3 weeks | Renal | 38 | 5 partial responses | ||
MDX-010 | 3 mg/kg | Melanoma | 7 | 0 | (57) |
Ovarian | 2 | 0 | |||
MDX-010 | 3 mg/kg every 4 weeks | Melanoma | 37 | 2 partial responses | (69) |
MDX-010 + dacarbazine | Melanoma | 35 | 1 complete response | ||
5 partial responses | |||||
MDX-010 | 1-3 mg/kg | Renal | 61 | 7 | (64) |
MDX-010 ± gp100 peptide | 1-9 mg/kg | Melanoma | 137 | 20 | |
MDX-010 + gp100 peptide | 3 mg/kg every 3 weeks | Melanoma | 14 | 2 complete responses | (61) |
1 partial response | |||||
MDX-010 + gp100 peptide | 3 mg/kg every 3 weeks | Melanoma | 29 | 2 complete responses | (60) |
2 partial responses | |||||
1-3 mg/kg, 1 mg/kg every 3 weeks | Melanoma | 27 | 3 partial responses | ||
MDX-010 + IL-2 | 1 mg/kg × 3-6 | Melanoma | 6 | 1 partial response | (65) |
2 mg/kg × 3-7 | Melanoma | 3 | 1 complete response | ||
3 mg/kg × 1-9 | Melanoma | 27 | 2 complete responses | ||
4 partial responses | |||||
MDX-010 + peptide | 0.3-3 mg/kg every 3 weeks | Melanoma | 19 | 7 | (62) |
MDX-010 + GVAX | 3 mg/kg | Prostate | 6 | 5 (≥50% decrease of prostate-specific antigen) | (70) |
CP-675,206 | 0.01-15 mg/kg × 1 | Melanoma | 34 | 2 complete responses | (59) |
2 partial responses | |||||
Renal | 4 | 0 | |||
Colon | 1 | 0 | |||
CP-675, 206 | 3-10 mg/kg every 4 weeks | Melanoma | 14 | 1 | (67) |
CP-675, 206 | 10 mg/kg every 4 weeks | Melanoma | 16 | 3 | (68) |
15 mg/kg every 12 weeks | Melanoma | 10 | 2 |